Home LiteratureArticle Details
PMID: 19794001 Published · ppublish English Editorial

Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.

Diabetes care ·Vol. 32 ·No. 10 ·2009-10-00 ·Pages 1753-68

Bresson D, von Herrath M

Abstract

暂无摘要

MeSH Terms
Animals Autoantibodies/immunology Biomedical Research/methods Clinical Trials as Topic Diabetes Mellitus, Type 1/immunology,metabolism,prevention & control,therapy Disease Models, Animal Humans Immunotherapy/methods Mice Mice, Inbred NOD Mice, Knockout
Chemicals
Autoantibodies islet cell antibody
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Bresson Damien
von Herrath Matthias
References (126)
126 references, click to expand
  1. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes.
    Nat Rev Immunol. 2004 Dec;4(12):989-97 PMID: 15573133
  2. Humanized NOD/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research.
    Ann N Y Acad Sci. 2007 Apr;1103:77-89 PMID: 17332083
  3. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes.
    Nature. 1998 Jan 8;391(6663):177-81 PMID: 9428763
  4. Effect of adjuvant therapy on development of diabetes in mouse and man.
    Lancet. 1994 Mar 19;343(8899):706-7 PMID: 7907682
  5. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.
    J Diabetes Complications. 2005 Jul-Aug;19(4):238-46 PMID: 15993359
  6. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health.
    J Clin Invest. 2004 Feb;113(3):451-63 PMID: 14755342
  7. Visualizing antigen specific CD4+ T cells using MHC class II tetramers.
    J Vis Exp. 2009 Mar 06;(25): PMID: 19270641
  8. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
    Diabetes Metab Res Rev. 2007 May;23(4):292-8 PMID: 17124720
  9. Methods to characterize lymphoid apoptosis in a murine model of autoreactivity.
    J Immunol Methods. 2005 Nov 30;306(1-2):137-50 PMID: 16242708
  10. Animal models for autoimmune myocarditis and autoimmune thyroiditis.
    Methods Mol Med. 2004;102:175-93 PMID: 15286386
  11. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
    Diabetes Care. 2005 May;28(5):1068-76 PMID: 15855569
  12. Rat models of type 1 diabetes: genetics, environment, and autoimmunity.
    ILAR J. 2004;45(3):278-91 PMID: 15229375
  13. Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes.
    Clin Immunol. 2008 May;127(2):138-43 PMID: 18304876
  14. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.
    J Clin Invest. 2007 Dec;117(12):3857-67 PMID: 18060033
  15. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus.
    Lancet. 1985 Jan 12;1(8420):67-71 PMID: 2857024
  16. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice.
    Cell Transplant. 2008;17(6):631-40 PMID: 18819251
  17. Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes.
    Curr Opin Mol Ther. 2008 Oct;10(5):516-25 PMID: 18830927
  18. Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration.
    J Autoimmun. 1998 Apr;11(2):127-30 PMID: 9650091
  19. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.
    Diabetologia. 2000 Aug;43(8):1000-4 PMID: 10990077
  20. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
    JAMA. 2007 Apr 11;297(14):1568-76 PMID: 17426276
  21. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes.
    Diabetes. 1998 Jan;47(1):39-44 PMID: 9421372
  22. Infectious tolerance.
    Curr Opin Immunol. 1998 Oct;10(5):518-24 PMID: 9794831
  23. Heat shock protein therapy fails to prevent diabetes in NOD mice.
    Diabetologia. 2002 Sep;45(9):1350-1 PMID: 12242470
  24. Humanized mice in translational biomedical research.
    Nat Rev Immunol. 2007 Feb;7(2):118-30 PMID: 17259968
  25. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects.
    Diabetes. 2002 May;51(5):1375-82 PMID: 11978633
  26. High dose nicotinamide fails to prevent diabetes in BB rats.
    Autoimmunity. 1989;5(1-2):79-86 PMID: 2535259
  27. Type 1 diabetes in the BB rat: a polygenic disease.
    Diabetes. 2009 Apr;58(4):1007-17 PMID: 19168599
  28. Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse.
    Methods Mol Biol. 2007;380:285-311 PMID: 17876100
  29. Intranasally administered insulin intended for prevention of type 1 diabetes--a safety study in healthy adults.
    Diabetes Metab Res Rev. 2003 Sep-Oct;19(5):415-20 PMID: 12951650
  30. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.
    J Exp Med. 2004 Jun 7;199(11):1455-65 PMID: 15184499
  31. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.
    Scand J Immunol. 2006 Jan;63(1):59-69 PMID: 16398702
  32. Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments. Comparative efficiency of human insulin and two bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae.
    Diabetes Metab. 1996 Oct;22(5):341-8 PMID: 8896996
  33. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4.
    J Clin Invest. 1999 Nov;104(10):1449-57 PMID: 10562307
  34. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.
    J Clin Invest. 2008 Oct;118(10):3390-402 PMID: 18802479
  35. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
    Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):123-7 PMID: 8278351
  36. Immunosuppressive drugs and the risk of cancer after organ transplantation.
    N Engl J Med. 2005 Mar 31;352(13):1371-3 PMID: 15800234
  37. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
    Diabetes Metab Res Rev. 2007 May;23(4):276-85 PMID: 17103487
  38. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
    Lancet. 2004 Mar 20;363(9413):925-31 PMID: 15043959
  39. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice.
    Diabetes. 2002 Mar;51(3):638-45 PMID: 11872661
  40. The Environmental Determinants of Diabetes in the Young (TEDDY) Study.
    Ann N Y Acad Sci. 2008 Dec;1150:1-13 PMID: 19120261
  41. Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the diabetes prevention trial-type 1 (DPT-1).
    Diabetes. 2008 Sep;57(9):2348-59 PMID: 18556337
  42. "Humanized" HLA transgenic NOD mice to identify pancreatic beta cell autoantigens of potential clinical relevance to type 1 diabetes.
    Ann N Y Acad Sci. 2007 Apr;1103:103-11 PMID: 17376821
  43. Islet autoreactive CD8 T-cells in type 1 diabetes: licensed to kill?
    Diabetes. 2008 May;57(5):1156 PMID: 18443371
  44. The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins.
    Diabetologia. 1988 Oct;31(10):747-50 PMID: 3240835
  45. Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal.
    Diabetologia. 2004 Oct;47(10):1650-6 PMID: 15490110
  46. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription.
    J Clin Invest. 1995 Feb;95(2):628-34 PMID: 7860747
  47. Magnetic resonance-guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells.
    Nat Med. 2007 Aug;13(8):986-91 PMID: 17660829
  48. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
    J Immunol. 2008 Mar 1;180(5):2863-75 PMID: 18292508
  49. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes.
    Diabetes Care. 2004 Oct;27(10):2348-55 PMID: 15451899
  50. Autoantibodies in diabetes.
    Diabetes. 2005 Dec;54 Suppl 2:S52-61 PMID: 16306341
  51. Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function.
    Pharm Res. 2006 Sep;23(9):1970-82 PMID: 16906455
  52. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice.
    Diabetes. 1998 Jun;47(6):894-9 PMID: 9604865
  53. Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes.
    Clin Exp Immunol. 2007 Apr;148(1):1-16 PMID: 17349009
  54. Detection of autoreactive T cells in type 1 diabetes using coded autoantigens and an immunoglobulin-free cytokine ELISPOT assay: report from the fourth immunology of diabetes society T cell workshop.
    Ann N Y Acad Sci. 2004 Dec;1037:10-5 PMID: 15699487
  55. A comprehensive review of interventions in the NOD mouse and implications for translation.
    Immunity. 2005 Aug;23(2):115-26 PMID: 16111631
  56. Animal models have little to teach us about type 1 diabetes: 2. In opposition to this proposal.
    Diabetologia. 2004 Oct;47(10):1657-60 PMID: 15502929
  57. CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes.
    Diabetes. 2007 Mar;56(3):613-21 PMID: 17327428
  58. The virtual NOD mouse: applying predictive biosimulation to research in type 1 diabetes.
    Ann N Y Acad Sci. 2007 Apr;1103:45-62 PMID: 17376834
  59. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. An observation in nonobese diabetic (NOD) mice.
    Diabetes. 1982 Sep;31(9):749-53 PMID: 6219022
  60. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?
    Autoimmun Rev. 2007 Apr;6(5):315-22 PMID: 17412305
  61. GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes.
    Diabetes. 2004 Aug;53(8):1987-94 PMID: 15277377
  62. Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes.
    Clin Exp Immunol. 2003 Oct;134(1):38-45 PMID: 12974752
  63. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells.
    Eur J Immunol. 1992 Apr;22(4):1013-22 PMID: 1348026
  64. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.
    Lancet. 2000 Aug 12;356(9229):545-9 PMID: 10950231
  65. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group.
    Diabetes. 1998 Jun;47(6):980-4 PMID: 9604880
  66. Type 1 diabetes.
    Lancet. 2006 Mar 11;367(9513):847-58 PMID: 16530579
  67. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.
    Clin Exp Immunol. 2007 Apr;148(1):17-31 PMID: 17349010
  68. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
    N Engl J Med. 2008 Oct 30;359(18):1909-20 PMID: 18843118
  69. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
    J Clin Invest. 2003 Feb;111(3):409-18 PMID: 12569167
  70. Transgenic animal models for type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse model.
    Transgenic Res. 2002 Dec;11(6):587-95 PMID: 12509133
  71. Effects of insulin in relatives of patients with type 1 diabetes mellitus.
    N Engl J Med. 2002 May 30;346(22):1685-91 PMID: 12037147
  72. A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis.
    J Immunol. 2001 Jun 15;166(12):7023-32 PMID: 11390446
  73. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
    Diabetes. 2005 Jun;54(6):1763-9 PMID: 15919798
  74. The DPT-1 trial: a negative result with lessons for future type 1 diabetes prevention.
    Diabetes Metab Res Rev. 2002 Jul-Aug;18(4):257-9 PMID: 12203941
  75. Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference.
    J Immunol. 1999 Aug 15;163(4):1833-8 PMID: 10438916
  76. Treatment with GAD65 or BSA does not protect against diabetes in BB rats.
    Autoimmunity. 1997;25(3):129-38 PMID: 9272278
  77. Do microbes have a causal role in type 1 diabetes?
    Med Sci Monit. 2005 Mar;11(3):RA63-9 PMID: 15735577
  78. Reversal of established autoimmune diabetes by restoration of endogenous beta cell function.
    J Clin Invest. 2001 Jul;108(1):63-72 PMID: 11435458
  79. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass.
    J Clin Endocrinol Metab. 2005 Jun;90(6):3401-9 PMID: 15769977
  80. B lymphocytes--chief players and therapeutic targets in autoimmune diseases.
    Front Biosci. 2008 May 01;13:4852-61 PMID: 18508550
  81. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism.
    Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13644-9 PMID: 18755894
  82. HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes.
    J Immunol. 2006 Mar 1;176(5):3257-65 PMID: 16493087
  83. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.
    PLoS One. 2008 Jun 18;3(6):e2435 PMID: 18560516
  84. Acceleration of the development of diabetes in obese diabetic (db/db) mice by nicotinamide: a comparison with its antidiabetic effects in non-obese diabetic mice.
    Metabolism. 2000 Dec;49(12):1548-54 PMID: 11145115
  85. Liposome-mediated transfer of IL-1 receptor antagonist gene to dispersed islet cells does not prevent recurrence of disease in syngeneically transplanted NOD mice.
    Cytokine. 2000 Apr;12(4):405-8 PMID: 10805224
  86. Animal models of type 1 diabetes are relevant to human IDDM--use caution.
    Diabetes Metab Rev. 1998 Jun;14(2):189-90 PMID: 9679673
  87. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response.
    Cell. 1991 Apr 19;65(2):319-31 PMID: 1901765
  88. Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice.
    Autoimmunity. 1997;26(3):139-51 PMID: 9550282
  89. Dosing and timing effects of anti-CD40L therapy: predictions from a mathematical model of type 1 diabetes.
    Ann N Y Acad Sci. 2007 Apr;1103:63-8 PMID: 17376835
  90. The replication of beta cells in normal physiology, in disease and for therapy.
    Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):758-68 PMID: 17955017
  91. Prevention strategies for type 1 diabetes mellitus: current status and future directions.
    BioDrugs. 2003;17(1):39-64 PMID: 12534319
  92. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes.
    Clin Exp Immunol. 2008 Jun;152(3):488-97 PMID: 18422727
  93. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
    N Engl J Med. 2002 May 30;346(22):1692-8 PMID: 12037148
  94. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.
    Cell. 1991 Apr 19;65(2):305-17 PMID: 1901764
  95. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
    N Engl J Med. 2005 Jun 23;352(25):2598-608 PMID: 15972866
  96. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes.
    J Autoimmun. 1994 Oct;7(5):655-63 PMID: 7840857
  97. Animal models of insulin-dependent diabetes.
    Methods Mol Med. 2004;102:195-212 PMID: 15286387
  98. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.
    J Clin Invest. 2006 May;116(5):1371-81 PMID: 16628253
  99. Exendin-4 modulates diabetes onset in nonobese diabetic mice.
    Endocrinology. 2008 Mar;149(3):1338-49 PMID: 18063685
  100. Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice.
    J Clin Invest. 1997 Sep 15;100(6):1344-8 PMID: 9294099
  101. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
    Lancet. 2008 Nov 15;372(9651):1746-55 PMID: 18814906
  102. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway.
    Immunity. 1999 Oct;11(4):463-72 PMID: 10549628
  103. Infections and autoimmune diseases.
    J Autoimmun. 2005;25 Suppl:74-80 PMID: 16278064
  104. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
    Endocrinology. 2007 Nov;148(11):5136-44 PMID: 17673522
  105. Development of type 1 diabetes despite severe hereditary B-cell deficiency.
    N Engl J Med. 2001 Oct 4;345(14):1036-40 PMID: 11586956
  106. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model.
    J Clin Invest. 2006 Jun;116(6):1506-13 PMID: 16710474
  107. Genetic susceptibility to type 1 diabetes.
    Curr Opin Immunol. 2005 Dec;17(6):601-8 PMID: 16226440
  108. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes.
    J Clin Invest. 2005 Sep;115(9):2454-61 PMID: 16110329
  109. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis.
    Cell Mol Life Sci. 2005 Aug;62(16):1850-62 PMID: 15968469
  110. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
    Clin Immunol. 2006 Sep;120(3):247-59 PMID: 16797237
  111. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance.
    J Immunol. 2002 Jan 15;168(2):933-41 PMID: 11777992
  112. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice.
    Diabetes. 2005 Sep;54(9):2596-601 PMID: 16123347
  113. HLA Class II molecules on haplotypes associated with type 1 diabetes exhibit similar patterns of binding affinities for coxsackievirus P2C peptides.
    Immunology. 2005 Nov;116(3):337-46 PMID: 16236123
  114. Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.
    Ann N Y Acad Sci. 2006 Oct;1079:369-73 PMID: 17130581
  115. The NOD mouse: a model of immune dysregulation.
    Annu Rev Immunol. 2005;23:447-85 PMID: 15771578
  116. New genetic and metabolic insights into animal models of diabetes. Proceedings of the 9th International Workshop on Lessons from Animal Diabetes. June 17-21, 2003. Bar Harbor, Maine, USA.
    Exp Diabesity Res. 2003 Jul-Sep;4(3):133-99 PMID: 15116738
  117. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice.
    Clin Exp Immunol. 1997 May;108(2):314-7 PMID: 9158104
  118. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro.
    Diabetes. 1999 Sep;48(9):1730-6 PMID: 10480601
  119. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.
    Clin Exp Immunol. 2009 Feb;155(2):156-65 PMID: 19040615
  120. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse.
    J Autoimmun. 2001 Feb;16(1):21-8 PMID: 11221993
  121. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.
    Diabetes. 2008 Dec;57(12):3281-8 PMID: 18835930
  122. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells.
    J Clin Invest. 2008 May;118(5):1806-14 PMID: 18431516
  123. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23).
    Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):956-60 PMID: 8570667
  124. Combination therapy with epidermal growth factor and gastrin delays autoimmune diabetes recurrence in nonobese diabetic mice transplanted with syngeneic islets.
    Transplant Proc. 2008 Mar;40(2):529-32 PMID: 18374121
  125. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide.
    Diabetes. 2002 Jul;51(7):2126-34 PMID: 12086942
  126. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
    Lancet. 2001 Nov 24;358(9295):1749-53 PMID: 11734230
Article Info
Journal
Diabetes care
Abbr.
Diabetes Care
ISSN
1935-5548
DOI
10.2337/dc09-0373
Published
2009-10-00
Pages
1753-68
Language
English
Region
United States
NLM ID
7805975
PMCID
PMC2752914
Subset
IM
Corrections
CommentIn
PMID: 19794002
External Links
PubMed source DOI: 10.2337/dc09-0373 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2